Novo Nordisk enters collaboration with AI-driven drug discovery company

Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis. 
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

Danish drugmaker Novo Nordisk has partnered with Hong Kong-based Insilico Medicine, an AI-driven drug discovery company, to develop new drugs against liver fibrosis. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading